BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael Bristow, President and Chief Executive Officer, has been selected to present in the “Update from Industry” session at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), being held in Gothenburg, Sweden, May 21 – 24, 2011. Dr. Bristow’s presentation, on Sunday, May 22, 2011, is entitled “Pharmacogenetic Targeting of Bucindolol in Heart Failure and Atrial Fibrillation.”
